Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 9, 2026, with voting rights for shareholders of record as of April 22, 2026.

• Board urges shareholders to vote for three highly qualified nominees aligned with the company's 5x30 growth strategy.

• DOMA Perpetual Capital Management is running a competing slate of director nominees, criticized for lack of relevant experience and a clear plan.

• The board highlights recent engagement with DOMA and reaffirms its commitment to sustainable growth and value creation.

• Forward-looking statements emphasize ongoing execution of strategic initiatives and product pipeline development.

Voting matters and shareholder proposals

• Shareholders are asked to elect three board nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans.

• Board recommends voting only for its nominees using the BLUE proxy card and not supporting DOMA's candidates.

• Proxy solicitation materials and voting instructions provided, with D.F. King & Co. as proxy solicitor.

Board of directors and corporate governance

• Board will comprise nine directors, eight of whom will be independent if the recommended nominees are elected.

• Five independent directors have joined within the last three years, reflecting board refreshment.

• Nominees bring expertise in government, public health, drug development, M&A, and biopharmaceutical leadership.

• Board conducted interviews with DOMA's nominees and found them underqualified; one nominee did not participate.